All In Biotech

Drug Trial Radar · NCT07477743

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Phase Ib Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HC010 Combinations in Patients With Advanced Solid Tumors and Determine the Recommended Dose for Subsequent Studies.

Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

331

Planned (sponsor's estimate)

Start

Mar 17, 2026

Primary completion

Dec 31, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
HC Biopharma Inc.Industry
Sponsor type
Industry
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced gastrointestinal cancer and determine the recommended dose for subsequent studies.

Conditions

  • Advanced Solid Tumor Cancer

Interventions

  • HC010Drug

    HC010 once every 3 weeks (Q3W) by intravenous drip

  • PaclitaxelDrug

    the combination chemotherapy regimens are all commonly used in clinical practice

  • OxaliplatinDrug

    the combination chemotherapy regimens are all commonly used in clinical practice

  • CapecitabineDrug

    the combination chemotherapy regimens are all commonly used in clinical practice

  • HC006Drug

    HC006 once every 3 weeks (Q3W) by intravenous drip

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs)Time frame: From first dose to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.